Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD997, a novel, selective mineralocorticoid receptor modulator
British journal of clinical pharmacology | 23 Feb 2018
F Erlandsson, M Albayaty, L Chialda, H Ericsson, C Amilon, K Nelander, R Jansson-Löfmark, L Wernevik, M Kjaer, K Bamberg and J Hartleib-Geschwindner
AZD9977 is the first MR modulator in clinical development exerting similar organ protection as eplerenone with minimal urinary electrolyte effects in pre-clinical studies. The aim was to perform the initial clinical assessment of AZD9977.
* Data courtesy of Altmetric.com